Phaseline

Companies › Gilead Sciences

Gilead Sciences: clinical trials, targets and expected readouts

49 active drug programs in 209 registered trials: 104 Phase 2, 49 Phase 1, 37 Phase 3, 19 Phase 4; Oncology, Infectious disease, Neurology, Immunology; next expected readout Nov 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Cobicistat
Cytochrome P450 3A inhibitor
CYP3A4, CYP3A5, CYP3A43, CYP3A7Phase 4HIV-1-infection; AML, AdultJun 2027
F/TAF (High Dose Tablet)
Nucleoside reverse transcriptase inhibitor (NRTI) combination: emtricitabine + tenofovir a
–Phase 4HIV-1-infectionJun 2027
Sacituzumab Govitecan
Tumor-associated calcium signal transducer 2 binding agent; DNA topoisomerase I inhibitor
TACSTD2, TOP1Phase 3Metastatic Breast Cancer; Non-Small Cell Lung Cancer; Triple Negative Breast Cancer; Locally Advanced or Unresectable Metastatic Breast Cancer …Dec 2026
Zimberelimab
Programmed cell death protein 1 inhibitor
PDCD1Phase 3Non-small Cell Lung Cancer; Head and Neck Squamous Cell Carcinoma; Advanced Non-Small Cell Lung Cancer; Lung Cancer …Dec 2026
Domvanalimab
T-cell immunoreceptor with Ig and ITIM domains inhibitor
TIGITPhase 3Non-small Cell Lung Cancer; Head and Neck Squamous Cell Carcinoma; Advanced Non-Small Cell Lung Cancer; Lung Cancer …Mar 2027
Lenacapavir
Structural capsid protein inhibitor
CA, CPSF6, GAG, PROT, UNKNOWN, CAPSIDPhase 3Pre-Exposure Prophylaxis of HIV Infection; HIV Pre-exposure Prophylaxis; HIV Infections; HIV-1-infection …Mar 2027
Bictegravir
Human immunodeficiency virus type 1 integrase inhibitor
INTEGRASE, ABCC10Phase 3HIV-1-infection; HIV-1 Infection; HIV -1 Infection; HIV InfectionsJun 2027
Tenofovir Disoproxil Fumarate
Human immunodeficiency virus type 1 reverse transcriptase inhibitor
POLA1, POLBPhase 3Chronic Hepatitis B; Hepatitis B; Hepatitis B Infection; Parkinson DiseaseJul 2027
Emtricitabine
Human immunodeficiency virus type 1 reverse transcriptase inhibitor
POLR2A, POLR1CPhase 3Pre-Exposure Prophylaxis of HIV Infection; Hiv; Alcohol Use, Unspecified; Pre-exposure Prophylaxis …Jan 2028
Islatravir
Reverse transcriptase inhibitor; Human immunodeficiency virus type 1 reverse transcriptase inhibitor
RT, IN, POLB, INTS1, INTS8Phase 3HIV-1-Infection; HIV-1-infection; HIV-1 InfectionMar 2028
anitocabtagene autoleucel
BCMA-directed CAR-T cell therapy
BCMAPhase 3Multiple Myeloma; Muscular DiseasesJul 2028
Seladelpar
Peroxisome proliferator-activated receptor delta agonist
PPARDPhase 3Primary Biliary Cirrhosis; Primary Biliary CholangitisNov 2028
Teropavimab
Anti-gp120 monoclonal antibody
ENVPhase 3HIV Infections; HIV-1-infection; HIV-1 InfectionMar 2029
Zinlirvimab
Envelope protein inhibitor
ENVPhase 3HIV Infections; HIV-1-infection; HIV-1 Infection; HIV/AIDS and Infections …Mar 2029
KITE-753
Anti-CD19 CAR-T cell therapy
CD19Phase 3Relapsed or Refractory Large B-cell Lymphoma; Relapsed and/or Refractory B-cell LymphomaFeb 2030
Axicabtagene Ciloleucel
B-lymphocyte antigen CD19 binding agent
CD19Phase 3Relapsed/Refractory Follicular Lymphoma; High-risk Large B-cell Lymphoma (LBCL); Lymphoma, B-Cell; B-Cell Lymphoma Refractory …Oct 2030
anitocabtagene-autoleucel–Phase 2Multiple Myeloma; Relapsed and Refractory Multiple MyelomaDec 2026
Tilpisertib
Mitogen-activated protein kinase kinase kinase 8 inhibitor
MAP3K8Phase 2Ulcerative ColitisJan 2027
ATV/co
HIV protease inhibitor boosted by cobicistat
PROTEASEPhase 2Acquired Immune Deficiency Syndrome (AIDS)Mar 2027
DRV/co
HIV protease inhibitor boosted by cobicistat
PROTEASEPhase 2Acquired Immune Deficiency Syndrome (AIDS)Mar 2027
Tenofovir Alafenamide
Human immunodeficiency virus type 1 reverse transcriptase inhibitor
POLRMT, RTPhase 2Acquired Immune Deficiency Syndrome (AIDS); Chronic Hepatitis B; Hepatitis B Reactivation; Chronic Hepatitis b …Mar 2027
Brexucabtagene Autoleucel (X19)
B-lymphocyte antigen CD19 binding agent
CD19Phase 2Relapsed/Refractory Mantle Cell Lymphoma; Mantle Cell Lymphoma; B-Cell Lymphoblastic Leukemia; Recurrent Mantle Cell Lymphoma …Jul 2027
GS-3242
HIV maturation inhibitor
–Phase 2HIV-1-infection; HIV-1 InfectionAug 2027
Quemliclustat
CD73 inhibitor
–Phase 2Advanced Non-Small Cell Lung CancerDec 2027
Lepetegravir
Integrase strand transfer inhibitor (INSTI)
INTEGRASEPhase 2HIV-1-InfectionJan 2028
ISL/LEN FDC
Fixed-dose combination of nucleotide reverse transcriptase translocation inhibitor and HIV
POLB, GAGPhase 2HIV-1 InfectionMar 2028
emvistegrast (GS-1427)
α4 integrin antagonist
ITGA4Phase 2Ulcerative ColitisApr 2028
Cilofexor
Bile acid receptor FXR agonist
NR1H4Phase 2Primary Biliary CholangitisDec 2028
Denikitug (GS-1811)–Phase 2Advanced Microsatellite Stable Colorectal Cancer; HER2-negative; Advanced Solid TumorDec 2028
Etrumadenant
Adenosine A2a receptor antagonist; Adenosine A2b receptor antagonist
ADORA2A, ADORA2BPhase 2Lung Cancer; Oligometastatic Prostate Cancer; Rectal Cancer; Pancreatic Ductal Adenocarcinoma …Sep 2029
BIC/LEN FDC
Combination of integrase strand transfer inhibitor and capsid inhibitor
INSR, POLLENPhase 2HIV-1-infectionDec 2029
KITE-197
CAR-T cell therapy targeting CD19
CD19Phase 1Relapsed/Refractory Large B-cell LymphomaNov 2026
GS-9911–Phase 1Solid TumorsDec 2026
GS-4571–Phase 1Weight ManagementFeb 2027
GS-0151–Phase 1Rheumatoid ArthritisMar 2027
TUB-040
NaPi2b antibody-drug conjugate (ADC)
SLC34A2Phase 1Ovarian CancerDec 2027
GS-5319
MTAP inhibitor
MTAPPhase 1Advanced Solid TumorMay 2028
GS-2121–Phase 1Advanced Solid TumorsJun 2028
GS-0201–Phase 1Advanced Solid TumorsSep 2028
TUB-030–Phase 1Advanced Solid TumorsDec 2028
GS-2426
MTAP inhibitor
MTAPPhase 1Advanced Solid TumorsJan 2029
KITE-363
CAR-T cell therapy targeting CD19
CD19Phase 1Chronic Inflammatory Demyelinating Polyneuropathy; Relapsed and/or Refractory B-cell LymphomaJun 2029
GS-0415
unclear - mechanism not stated in registry
–Phase 1HIV -1 InfectionAug 2029
GS-1206–Phase 1Solid TumorSep 2029
GS-4321–Phase 1Chronic Hepatitis DeltaJan 2030
ARC-T Cells
Autologous T cells with chimeric antigen receptor (CAR) binding to CD123 via soluble prote
–Phase 1Acute Myeloid Leukemia–
GS-4528–Phase 1Solid Tumor–
INT2104
CD20-targeting CAR (chimeric antigen receptor) delivered by lentiviral vector
CD20Phase 1Lymphomas Non-Hodgkin's B-Cell–
SPRX002
Soluble protein antigen-receptor X-linker with CD123-targeting binding region; serves as b
CD123Phase 1Acute Myeloid Leukemia–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT03489239Tenofovir AlafenamidePhase 3Hepatitis BInfectious diseaseAug 2020
NCT04531046Axicabtagene CiloleucelPhase 2B-Cell Lymphoma RefractoryOncologyApr 2022
NCT03343431Tenofovir Disoproxil FumaratePhase 3Hepatitis BInfectious diseaseMay 2023
NCT04616963EmtricitabinePhase 4HivInfectious diseaseJan 2024
NCT05824468ZimberelimabPhase 2Cervical CancerOncologyJul 2024
NCT04619082Tenofovir AlafenamidePhase 4Hepatitis B ReactivationInfectious diseaseDec 2024
NCT05853718Tenofovir AlafenamidePhase 4Chronic Hepatitis bInfectious diseaseDec 2025
NCT06356662Tenofovir Disoproxil FumaratePhase 1Parkinson DiseaseNeurologyDec 2025
NCT04331704EmtricitabinePhase 4Alcohol Use, UnspecifiedPsychiatryDec 2025
NCT07210528EmtricitabinePhase 1Mild Cognitive Impairment (MCI)NeurologySep 2026
NCT05119907Sacituzumab GovitecanPhase 2Solid TumorOncologyOct 2026
NCT05840224ZimberelimabPhase 1Solid TumorOncologyOct 2026
NCT05457010ARC-T CellsPhase 1Acute Myeloid LeukemiaOncologyOct 2026
NCT05457010SPRX002Phase 1Acute Myeloid LeukemiaOncologyOct 2026
NCT05840224GS-4528Phase 1Solid TumorOncologyOct 2026
NCT06539338INT2104Phase 1Lymphomas Non-Hodgkin's B-CellOncologyOct 2026
NCT06511063EmtricitabinePhase 2Long CovidInfectious diseaseNov 2026
NCT06079164KITE-197Phase 1Relapsed/Refractory Large B-cell LymphomaOncologyNov 2026
NCT05915442ZimberelimabPhase 2Oligometastatic Prostate CancerOncologyDec 2026
NCT05688215ZimberelimabPhase 1Borderline Resectable Pancreatic AdenocarcinomaOncologyDec 2026
NCT05915442EtrumadenantPhase 2Oligometastatic Prostate CancerOncologyDec 2026
NCT05300035ZinlirvimabPhase 2HIV/AIDS and InfectionsInfectious diseaseDec 2026
NCT04639986Sacituzumab GovitecanPhase 3Metastatic Breast CancerOncologyDec 2026
NCT03964727Sacituzumab GovitecanPhase 2Metastatic Solid TumorOncologyDec 2026
NCT04617522Sacituzumab GovitecanPhase 1Advanced or Metastatic Solid TumorOncologyDec 2026
NCT06104592Axicabtagene CiloleucelPhase 2Large B-cell LymphomaOncologyDec 2026
NCT05396885anitocabtagene-autoleucelPhase 2Multiple MyelomaOncologyDec 2026
NCT06082960ZimberelimabPhase 1Solid TumorsOncologyDec 2026
NCT05024097ZimberelimabPhase 2Rectal CancerOncologyDec 2026
NCT06048133ZimberelimabPhase 2Biliary Tract CarcinomaOncologyDec 2026
NCT05024097EtrumadenantPhase 2Rectal CancerOncologyDec 2026
NCT06082960GS-9911Phase 1Solid TumorsOncologyDec 2026
NCT06158126EmtricitabinePhase 4Pre-exposure ProphylaxisInfectious diseaseDec 2026
NCT06055738ZimberelimabPhase 2Locally Advanced Cervical CancerOncologyDec 2026
NCT04340596ZinlirvimabPhase 1HIV InfectionInfectious diseaseDec 2026
NCT06826118Axicabtagene CiloleucelPhase 2LymphomaOncologyDec 2026
NCT04496882Tenofovir AlafenamidePhase 4Chronic Hepatitis bInfectious diseaseDec 2026
NCT04704024Tenofovir Disoproxil FumaratePhase 3Hepatitis B InfectionInfectious diseaseDec 2026
NCT07349758EmtricitabinePhase 1Healthy VolunteerInfectious diseaseJan 2027
NCT05089734Sacituzumab GovitecanPhase 3Non-Small Cell Lung CancerOncologyJan 2027
NCT06029972TilpisertibPhase 2Ulcerative ColitisImmunologyJan 2027
NCT04780204Tenofovir AlafenamidePhase 4Hepatitis B, ChronicInfectious diseaseJan 2027
NCT07254754Axicabtagene CiloleucelPhase 2DIFFUSE LARGE B-CELL LYMPHOMAOncologyJan 2027
NCT05382286Sacituzumab GovitecanPhase 3Triple Negative Breast CancerOncologyFeb 2027
NCT06238921ZimberelimabPhase 1Breast CancerOncologyFeb 2027
NCT06562907GS-4571Phase 1Weight ManagementMetabolic and endocrineFeb 2027
NCT05186974Sacituzumab GovitecanPhase 2Non-small Cell Lung CancerOncologyMar 2027
NCT06727565ZimberelimabPhase 2Head and Neck Squamous Cell CarcinomaOncologyMar 2027
NCT07424664ZimberelimabPhase 2Uterine Cervical Neoplasms, Recurrent; Uterine Cervical Neoplasms, Metastatic; Vulvar Neoplasms; Vaginal NeoplasmsOncologyMar 2027
NCT06727565DomvanalimabPhase 2Head and Neck Squamous Cell CarcinomaOncologyMar 2027
NCT06749054LenacapavirPhase 2HIV-1-infectionInfectious diseaseMar 2027
NCT06749054LenacapavirPhase 2HIV-1-infectionInfectious diseaseMar 2027
NCT02016924Tenofovir AlafenamidePhase 2Acquired Immune Deficiency Syndrome (AIDS)Infectious diseaseMar 2027
NCT02016924ATV/coPhase 2Acquired Immune Deficiency Syndrome (AIDS)Infectious diseaseMar 2027
NCT02016924DRV/coPhase 2Acquired Immune Deficiency Syndrome (AIDS)Infectious diseaseMar 2027
NCT06902519GS-0151Phase 1Rheumatoid ArthritisImmunologyMar 2027
NCT07210125LenacapavirPhase 4HIVInfectious diseaseMar 2027
NCT05612178ZinlirvimabPhase 1HIV-1Infectious diseaseMar 2027
NCT06048484ZimberelimabPhase 2Pancreatic Ductal AdenocarcinomaOncologyApr 2027
NCT06048484EtrumadenantPhase 2Pancreatic Ductal AdenocarcinomaOncologyApr 2027

The 60 nearest readouts of 209 trials; the rest in the app.

From the company's SEC filings

Cash and short-term investments of $6.4bn on 2026-09-30; operating cash flow positive

Press releases filed as 8-K in the last year:

Regulatory dates the company has stated

Complete response letters from FDA

Agreements filed with the SEC (item 1.01), last two years

Specialist investors

Held by 6 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.

Targets

CD19 (5) POLB (3) RT (2) MTAP (2) GAG (2) ENV (2) INTEGRASE (2) PROTEASE (2) TACSTD2 (1) TOP1 (1) PPARD (1) SLC34A2 (1)

Companies with the same targets

Bristol-Myers Squibb Chongqing Precision Biotech Allogene Therapeutics Merck & Co. (MSD) Miltenyi Biomedicine GSK Amgen AstraZeneca Beijing Yongtai Ruike Biotechnology Company Shanghai Ming Ju Biotechnology

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.